Oxyntomodulin increases intrinsic heart rate through the glucagon receptor

Auyon Mukharji1, Daniel J. Drucker2, Maureen J. Charron3 & Steven J. Swoap1

1 Department of Biology, Williams College, Williamstown, Massachusetts
2 Department of Medicine, Samuel Lunenfeld Research Institute, Mt. Sinai Hospital, University of Toronto, Toronto, Canada
3 Departments of Biochemistry, Medicine, and Ob/Gyn and Women’s Health, Albert Einstein College of Medicine, New York, New York

Keywords
Beta block, GLP-1, OXM, sympathetic nervous system.

Abstract
Two hormones from the gastrointestinal tract, glucagon and oxyntomodulin (OXM), vigorously elevate the intrinsic heart rate (IHR) of mice. We have previously shown that OXM influences murine heart rate (HR) independent of the glucagon-like peptide 1 (GLP-1) receptor. Here, we demonstrate using radiotelemetry in mice deficient in the glucagon receptor (Gcgr−/−) that both OXM and glucagon require the glucagon receptor for their chronotropic effects on the heart. Furthermore, we found that other hormones associated with hunger and satiety (ghrelin, leptin, and PYY3-36) had no effect on IHR, while cholecystokinin moderately elevated the IHR. Finally, the resting HR of Gcgr−/− mice was higher than in control mice (Gcgr+/+ and Gcgr+/−) at thermal neutral temperature (30°C). Using atropine, we demonstrated that Gcgr−/− mice have diminished parasympathetic (PNS) influence of the heart at this temperature. Gcgr−/− mice displayed a normal bradycardia as compared to controls in response to administration of either methacholine (to activate the muscarinic acetylcholine receptor) or methoxamine (to activate the baroreflex through agonism of the α1 adrenergic receptor agonist) suggesting that vagal pathways are intact in the Gcgr−/− mice. As OXM is an agonist of the GLP-1 receptor and Gcgr with antidiabetic activity, we suggest OXM may be an alternative to glucagon in the treatment of overdose of beta-blockers to elevate HR in clinical conditions.

Introduction
The gastrointestinal tract is the body’s largest endocrine organ, and releases more than 20 different regulatory peptide hormones that act on a number of tissues, including exocrine glands, cardiac muscle, smooth muscle, and the peripheral nervous system (Murphy and Bloom 2006; Drucker 2007). The changes in the circulating levels of these gut hormones and the interactions between them are known to modulate numerous physiological functions. The most well studied of these functions are hunger and satiety (Cummings and Overduin 2007; Chaudhri et al. 2008; Karra and Batterham 2010). Because some gut hormones could be used as a therapeutic to either increase hunger, as in treatment of cachexia, or decrease hunger, as in treatment of obesity, it is important to identify other physiological systems that are affected by hunger-modulating hormones. In this study, we examined the effects of some of these hormones on the intrinsic heart rate (IHR) of mice.

Heart rate (HR) is governed by the interactions between the intrinsic HR and the autonomic nervous system, which is comprised of the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS). The IHR is the rate of contractions occurring under conditions of no nervous input on cardiac tissue.
Known modulators of I_{HR}, such as adenosine and thyroid hormone, are known to function by affecting specific channels or currents that determine the potential of the membrane (Belardinelli et al. 1995; Foley et al. 2001; De Angelis et al. 2004; Takayama et al. 2005). For example, the primary action of adenosine in sinoatrial node cells is the direct cAMP-independent activation of the inwardly rectifying potassium ion current, which slows the I_{HR} (Belardinelli et al. 1995).

Glucagon, a 29-amino acid pancreatic hormone derived from processing of proglucagon in the alpha cells of the islets of Langerhans, has long been known to elevate I_{HR} (Steiner et al. 1969; Stusse et al. 1982), which is also true in mice (Sowden et al. 2007). Because of its direct impact on the heart to increase HR independent of the SNS, glucagon is often used a first line of defense clinically to elevate HR in cases of beta-blocker poisoning (Newton et al. 2002; Watson et al. 2005; Shepard 2006; Kerns 2007). Glucagon has a great number of effects throughout the body of which most are mediated via a specific glucagon receptor, Gcgr, expressed in numerous tissues including the heart (Burcelin et al. 1995; Hansen et al. 1995; Dunphy et al. 1998; Mayo et al. 2003; Habegger et al. 2010). When glucagon binds its receptor, adenylyl cyclase is activated, increasing cAMP levels and activating a CAMP-dependent protein kinase (Macneil et al. 1994). While glucagon is probably best known for its effects on the liver in glucose homeostasis, the hormone also has a number of extrahepatic effects, including positive inotropic and chronotropic effects in the heart, increased lipolysis in adipose tissue, action as a satiety factor in the central nervous system, regulatory effects on glomerular filtration rate, and intraislet regulation of insulin, glucagon, and somatostatin secretion (Habegger et al. 2010; Heppner et al. 2010; Vuguin and Charron 2011).

Oxyntomodulin (OXM) is a 37-amino acid peptide containing the entire 29-amino acid sequence of glucagon followed by an eight amino acid carboxy-terminal extension and is released postprandially from the intestinal L-cells (Druce et al. 2004; Druce and Ghatei 2006; Pocai 2012). OXM dose-dependently inhibits food intake under normal and fasting conditions without delaying gastric emptying (Cohen et al. 2003; Dakin et al. 2004; Sowden et al. 2007). In addition to its effects on food intake, OXM strongly elevates HR without affecting blood pressure and lowers core body temperature (Sowden et al. 2007). OXM has a weak affinity for the Gcgr and the glucagon-like peptide 1 receptor (GLP-1R) (Dakin et al. 2001; Baggio et al. 2004). It is through the GLP-1R that OXM exerts its effects on satiety, elevates insulin secretion from β cells and lowers body temperature (Sowden et al. 2007; Maida et al. 2008). However, OXM accelerates murine HR independent of the autonomic nervous system through a GLP-1R-independent mechanism (Sowden et al. 2007).

This study was designed to (1) examine the effects of other gut hormones on the I_{HR} of mice, and (2) test the hypothesis that the cardiac effects of OXM are mediated through the Gcgr. We show here that the effect of OXM on I_{HR} requires 10× the dose of glucagon and is dependent upon the action of the Gcgr. We suggest OXM be considered for study in place of or in addition to the use of glucagon to elevate HR in human patients that have cardiotoxicity associated with an overdose of beta-blockers or calcium channel blockers.

**Materials and Methods**

**Animals**

Six adult female C57BL/6J mice, weighing ~25 g, were purchased from Jackson Labs (Bar Harbor, ME). Gcgr +/- mice used in this study were originally described by Gelling et al. (2003). Mice were housed individually at 30°C in a 12:12 h light–dark cycle and fed ad libitum on the Harlan Teklad (Madison, WI) mouse/rat laboratory diet. All procedures and experimental protocols were approved by the Williams College Animal Care and Use Committee.

**Genotyping**

The offsprings from four Gcgr +/- breeding pairs were genotyped. DNA was purified using from tail snips using a QIAamp Tissue Kit (Qiagen, Germantown, MD). The polymerase chain reaction (PCR) was run using a Ready-Mix (Sigma, St. Louis, MO). The primers used are listed in Table 1.

**Reagents**

Porcine OXM was obtained from California Peptide Research Inc. (Napa, CA). Glucagon, metoprolol, methacholine, methacholine, and atropine were obtained from Sigma.

**Implantation of ECG telemeters**

Mice were anesthetized with 2–3% isoflurane in an oxygen stream, and then maintained at ~2% isoflurane. The

| Table 1. Primers for genotyping Gcgr +/- progeny. |
|--------------------------------------------------|
| **Gcgr forward primer** | TCCCAATGTCAGTGGATGA |
| **Gcgr reverse primer** | AAGGTGAAGCAGCAATGGAG |
| **Neomycin cassette forward primer** | GTCTTTGATCATGGATCTCTG |
mice were kept on a heating pad throughout the implantation of the electrocardiogram (ECG) telemeters (ETAF20, weight 1.6 g with a volume of 1.1 cc, Data Sciences International, St. Paul, MN) in the abdominal cavity with subcutaneous placement of the leads. Mice were maintained on a heating pad for at least 24 h after surgery, and were then housed at 30°C for 10 days in order to ensure adequate recovery.

Cardiovascular, temperature, and activity data collection

Data from the ECG telemeters were sampled at 2000 Hz. Data were collected for 5 sec, once per minute. Data were collected for 12 h of the dark phase and 11 h of the light phase as the final hour of the light phase was reserved for animal care. For injections, data were taken from 30 min before the injection until 120 min afterward. Data were collected for 12 h of the dark phase and 11 h of the light phase. This injection was then followed 25 min later by an intraperitoneal injection of vehicle (saline), OXM or glucagon on IHR, mice deficient in Gcgr were examined. As OXM and glucagon both elevate IHR in mice (Steiner et al. 1969; Stuesse et al. 1982; Sowden et al. 2007), other peptides known to influence satiation were tested in mice to assess their effect on IHR. To measure IHR, C57Bl/6J mice were implanted with a telemeter to detect HR. After recovery from the surgery, mice were administered a cocktail of metoprolol and atropine. Mice were then given a second injection of a peptide or vehicle 25 min later. Measurements for IHR were obtained from tracings 15 min after injection of saline (40 min after injection of the cocktail, as shown on Fig. 1A). Figure 1A shows a typical HR response to either saline or 15 μg of glucagon after the autonomic block induced by metoprolol and atropine. As Figure 1B shows, three of the tested hormones, leptin, PYY3-36 and ghrelin, had no effect on IHR even at high doses (33, 100, and 100 μg, respectively). The most potent peptide tested was glucagon with a significant elevation in IHR at the lowest dose tested (0.3 μg). OXM also increased IHR with 15 μg and 15 μg, as did CCK at a dose of 10 μg.

Gcgr −/− mice exhibited elevated HRs at warm ambient temperatures

To determine whether the Gcgr mediates the action of OXM and glucagon on IHR, mice deficient in Gcgr were examined. Gcgr +/+, +/-, and −/− mice were implanted with telemeters to detect HR, core body temperature (Tb), and general cage activity. Measurements of these variables were made in the dark phase and light phase, while the mice were housed at an ambient temperature...
OXM, Glucagon, and Intrinsic HR

A. Mukharji et al.

Table 2. Physiological variables of control and Gcgr −/− mice.

|                              | Control mice | Gcgr −/− mice |
|------------------------------|--------------|---------------|
| Dark phase heart rate (bpm)  | 426 ± 18*    | 429 ± 16**    |
| Light phase heart rate (bpm) | 322 ± 7      | 357 ± 9*      |
| Dark phase core T<sub>b</sub> (°C)| 37.5 ± 0.2* | 37.2 ± 0.1**  |
| Light phase core T<sub>b</sub> (°C)| 35.9 ± 0.2  | 36.1 ± 0.1    |
| Dark phase activity (A.U.)   | 12.0 ± 4.0*  | 12.8 ± 3.0**  |
| Light phase activity (A.U.)   | 1.3 ± 0.4    | 3.5 ± 0.7     |

A.U. = arbitrary units.
*P < 0.05 versus light phase for control mice.
**P < 0.05 versus light phase for Gcgr −/− mice.

OXM and glucagon elevate IHR via the Gcgr

The IHR of control and Gcgr −/− male and female mice was next assessed. Within either genotype, no difference was found between genders. However, the IHR of control mice was significantly higher (Fig. 2A) than that of Gcgr −/− mice (430 ± 12 bpm vs. 382 ± 17 bpm, respectively). To examine whether glucagon and OXM elevate IHR via the Gcgr, both groups of mice received the metoprolol/atropine cocktail, followed 25 min later by a second intraperitoneal injection of either OXM (15 µg), or glucagon (1.5 µg). Glucagon vigorously increased the IHR (the time of measurement of IHR is shown in Fig. 2B) of control mice to 586 ± 42 bpm. As expected, glucagon did not alter the IHR of Gcgr −/− mice (394 ± 14 bpm).

Like glucagon, OXM robustly elevated IHR in control mice (430 ± 12 bpm vs. 382 ± 17 bpm). However, OXM had no effect on the IHR of Gcgr −/− mice, as their IHR remained at 381 ± 12 bpm (Fig. 2C).

Inappropriately low PNS to the heart in Gcgr −/− mice

Despite having a lower IHR (Fig. 2A), Gcgr −/− mice have a higher resting HR than control mice (Table 2). The elevated HR in Gcgr −/− mice could be the result of low PNS activity at the heart and/or the result of elevated SNS activity at the heart. To distinguish between these possibilities, mice received an intraperitoneal injection of either atropine to block the muscarinic receptor or metoprolol to block the β1 adrenergic receptor. Administration of atropine affected the two groups of mice differently. When atropine was injected into control mice, HR increased by 138 ± 28 bpm (Fig. 3A and B). This demonstrates the prominent role of the PNS in depressing HR in normal mice at the warm T<sub>b</sub> of 30°C (Swoap et al. 2008). However, atropine elevated the HR of Gcgr −/− mice only 53 ± 12 bpm (Fig. 3A and B), suggesting the influence of the PNS is diminished in these mice. Meto-
prolol had no effect on the HR of either control or Gcgr−/− mice (Fig. 3B), suggesting the SNS plays little role in modulating resting HR during the light phase at 30°C. Muscarinic signaling and vagal signaling are intact in Gcgr−/− mice

To further interrogate PNS function in Gcgr−/− mice, we examined the effect of methacholine and methoxamine on HR in control and Gcgr−/− mice. Administration of methacholine, an agonist of the muscarinic

**Figure 2.** OXM increases IHR through the Gcgr. Control mice and Gcgr−/− mice were implanted with ECG telemeters for measurement of heart rate. The mice received a cocktail of metoprolol and atropine at time “0” to block autonomic input to the heart. 25 min after metoprolol/atropine, mice received an intraperitoneal injection of either saline (A), 1.5 μg glucagon (B), or 15 μg OXM (C). Both glucagon and OXM elevated HR significantly in control mice, but neither of these peptides elevated HR in Gcgr−/− mice, demonstrating the requirement of the Gcgr for this effect.

**Figure 3.** Parasympathetic activity is low in Gcgr−/− mice. Mice were housed at 30°C and received an intraperitoneal injection of either atropine to block PNS activity or with metoprolol to block only SNS activity. In part (A), a typical tracing from a Control mouse and a typical tracing from a Gcgr−/− mouse are shown in response to atropine. Tracings like those shown in part (A) were collected from all mice and the elevation in heart rate was calculated. As expected, metoprolol had no effect on HR as SNS activity is minimal at this warm Ta. Atropine, however, elevated heart rate in control mice to a much greater extent than in Gcgr−/− mice suggesting the PNS plays a lesser role in governing heart rate in Gcgr−/− mice than in control mice. *P < 0.05 versus control mice.
receptor, lowered HR within the first minute (Fig. 4A) in control and Gcgr −/− mice. Methacholine resulted in a similar time course and minimum HR for control and Gcgr −/− mice (138 ± 5 bpm and 132 ± 3 bpm, respectively) suggesting signaling from the muscarinic receptor is intact in Gcgr −/− mice. Administration of methoxamine, an agonist of the α1 adrenergic receptor, elevates blood pressure resulting in a reflex fall in HR that is mediated through the vagus nerve. Administration of methoxamine lowered HR in control mice (Fig. 4B) to 221 ± 13 bpm. The HR of Gcgr −/− mice fell to the same extent (201 ± 7 bpm) over the same time course as control mice (Fig. 4B), suggesting signaling through the vagus nerve is not impaired in Gcgr −/− mice. These results suggest the low PNS activity in Gcgr −/− mice is not a function of decreased vagal activity or impaired muscarinic receptor signaling.

Discussion

As more is learned about the neuroendocrine control of hunger, and therapeutics are designed to manipulate the satiation status of individuals, it is important to consider the possible cardiac side effects of these interventions. Indeed, obesity is an independent predictor of tachycardia which is itself a strong predictor of excessive coronary morbidity and of cardiovascular mortality (Palatini et al. 1997). Examined herein are the effects of a subset of these hormones on one aspect of the cardiovascular system, IHR. Two anorectic hormones tested here, PYY3-36 and leptin, had no effect on murine IHR. The hunger-inducing hormone, ghrelin, similarly had no effect. CCK, which decreases hunger, has been shown to lower resting HR, with those actions mediated through the CCK-A receptor (Kurosawa et al. 2001). Thus, it was surprising to learn that CCK modestly elevates IHR (Fig. 1B). To lower HR in the face of an elevated IHR, CCK must elevate to a great extent the vagal outflow to the heart. The last two peptide hormones tested were glucagon and OXM, both previously known to elevate IHR (Steiner et al. 1969; Stu-esse et al. 1982; Sowden et al. 2007). The finding that these hormones increase IHR was confirmed here, with new information regarding the relative potency of these hormones on the heart (i.e., glucagon>OXM>CCK).

OXM can inhibit food intake, elevate metabolic rate, and cause weight loss when administered peripherally in humans, sparking interest in the use of OXM or related glucagon-GLP-1 receptor co-agonists as a potential therapy for obesity (Wynne et al. 2005, 2006). We and others have shown that OXM induces satiation through the GLP-1 receptor (Baggio et al. 2004; Sowden et al. 2007), so we were surprised that OXM did not require the GLP-1 receptor to elevate IHR (Sowden et al. 2007). Because (1) OXM contains the identical amino acid sequence of glucagon, with an additional eight amino acids, (2) OXM has a weak affinity for the Gcgr, and (3) glucagon elevates IHR, we reasoned that the action of OXM on IHR might be mediated through the Gcgr. To test this hypothesis, we measured the impact of glucagon and OXM on the IHR in mice deficient in the Gcgr (Gelling et al. 2003). Gcgr −/− are viable, but have reduced plasma glucose levels, improved glucose tolerance, are resistant to diet-induced
obesity, have elevated GLP-1 levels, and do not have normal fat metabolic control during a fast (Parker et al. 2002; Gelling et al. 2003; Sørensen et al. 2006; Vugun et al. 2006; Conarello et al. 2007; Longuet et al. 2008). We show here unambiguously that neither OXM nor glucagon can modulate the $I_{\text{HR}}$ of $G_{\text{cgr}}$ −/− mice. These findings suggest glucagon and OXM mediate their cardiac effects through the $G_{\text{cgr}}$.

Overdoses of cardiovascular drugs are associated with morbidity and mortality. The most significant of those cardiovascular drugs are “beta-blockers” and “calcium channel blockers”. Individuals that take an overdose of these drugs include unknowing children, accidental dosing by a patient, and those trying to commit suicide. In 2004, the number of overdoses of drug-related toxic exposure to either beta-blockers or calcium channel blockers was 27,500 individuals (Watson et al. 2005). The first line of defense in an overdose of beta-blockers is glucagon injection (DeWitt and Waksman 2004; Shepard 2006) because of its inotropic and chronotropic effects on the heart independent of the beta adrenergic receptor, which is blocked in the overdose case (Kerns 2007). Glucagon is also used in combination with other antidotes in the case of an overdose of calcium channel blockers (Newton et al. 2002). However, glucagon administration in overdose cases does not consistently improve survival (Shepard 2006; Kerns 2007). Administration of glucagon to elevate HR in a beta-blocked patient can induce hyperglycemia (Taboulet et al. 1993), and so it should not be overlooked that OXM may have clinical value for these situations as OXM has antidiabetic properties associated with activating the GLP-1R (Maida et al. 2008; Pocai 2012). While glucagon is a major regulator of blood glucose, this hormone has many other effects not consistent with its counterregulatory effects to insulin (Jones et al. 2012). Alternatives to glucagon, like OXM, for positive chronotropic effects may be particularly advantageous over glucagon in humans with impaired insulin secretion (Cryer 2012; Pocai 2012). However, it should be noted that the dosage for OXM used in this study to impact murine HR is many orders of magnitude higher than that used in humans to impact satiation (Wynne et al. 2005, 2006).

While typical vivarium conditions house small rodents well below their thermoneutral zone, mice were housed in this study at 30°C. At this $T_a$, HR is much lower than $I_{\text{HR}}$ and much lower than when mice are housed at cooler $T_a$s (Williams et al. 2002; Swoap et al. 2008). In wild-type mice, the bradycardia with exposure to a warm environment is a result of an increased cardiac influence of the PNS via the vagus nerve and decreased influence of the SNS. Two pieces of evidence suggest that PNS activity to the $G_{\text{cgr}}$ −/− mouse heart is diminished: (1) the elevated HR in the light phase in $G_{\text{cgr}}$ −/− mice at 30°C (Table 2), when PNS activity is at its greatest, and (2) the only modest elevation in HR response to atropine (Fig. 3A and B), an antagonist of the muscarinic receptor on the heart. Many potential levels along the PNS chain could be responsible for the lack of cardiac suppression in $G_{\text{cgr}}$ −/− mice housed near their thermoneutral zone. These levels include acetylcholine insensitivity, lack of acetylcholine release, some other defect in the vagus nerve itself, generation of the initial action potentials within the brainstem, or sensory inputs into the PNS center. We show here that signaling through the vagus nerve appears normal because $G_{\text{cgr}}$ −/− mice responded normally to methoxamine (Fig. 4). This compound is a potent vasoconstrictor that elevates blood pressure and induces a reflex fall in HR via the vagus nerve. Similarly, the signaling at the heart through the muscarinic receptor seems normal because $G_{\text{cgr}}$ −/− mice responded normally to methacholine, a muscarinic receptor agonist (Fig. 4). It remains to be determined whether afferent nerve activity reporting temperature (external or internal) is somehow impaired in $G_{\text{cgr}}$ −/− mice, or some defect further downstream from temperature sensation. However, our data suggest that activity from the vagus nerve and activity at the cardiac muscarinic receptor are not impaired.

To summarize, OXM is a potent appetite suppressant. Its satiation activity is mediated through the GLP-1R (Cohen et al. 2003; Dakin et al. 2004; Sowden et al. 2007). OXM also robustly elevates the $I_{\text{HR}}$ of a mouse. Although the majority of glucagoregulatory actions of OXM are mediated through the GLP-1R (Maida et al. 2008; Pocai 2012), we show here that the cardiac effects of OXM (and glucagon) are mediated through the $G_{\text{cgr}}$. It is also suggested that OXM may be an excellent alternative to glucagon for the therapeutic treatment of acute overdose of beta-blockers.

Conflict of Interest
None declared.

References
Baggio, L. L., Q. Huang, T. J. Brown, and D. J. Drucker. 2004. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127:546–558.
Belardinelli, L., J. Shryock, Y. Song, D. Wang, and M. Srinivas. 1995. Ionic basis of the electrophysiological actions of adenosine on cardiomyocytes. FASEB J. 9:359–365.
Burcelin, R., J. Li, and M. J. Charron. 1995. Cloning and sequence analysis of the murine glucagon receptor-encoding gene. Gene 164:305–310.
Dunphy, J. L., R. G. Taylor, and P. J. Fuller. 1998. Tissue
Drucker, D. J. 2007. The role of gut hormones in glucose
Druce, M. R., C. J. Small, and S. R. Bloom. 2004. Minireview:
Druce, M. R., and M. Ghatei. 2006. Oxyntomodulin. Curr.
DeWitt, C. R., and J. C. Waksman. 2004. Pharmacology,
Dakin, C. L., C. J. Small, R. L. Batterham, N. M. Neary,
Page 8
2013 | Vol. 1 | Iss. 5 | e00112

OXM, Glucagon, and Intrinisic HR

Charles, O. B., V. Salem, K. G. Murphy, and S. R. Bloom. 2008. Gastrointestinal satiety signals. Annu. Rev. Physiol. 70:239–255.
Cohen, M. A., S. M. Ellis, C. W. le Roux, R. L. Batterham, A. Park, M. Patterson, et al. 2003. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88:4696–4701.
Conarello, S., G. Jiang, J. Mu, Z. Li, J. Woods, E. Zycband, et al. 2007. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50:142–150.
Cryer, P. E. 2012. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 153:1039–1048.
Cummings, D. E., and J. Overduin. 2007. Gastrointestinal regulation of food intake. J. Clin. Invest. 117:13–23.
Dakin, C. L., I. Gunn, C. J. Small, C. M. B. Edwards, D. L. Hay, D. M. Smith, et al. 2001. Oxyntomodulin inhibits food intake in the rat. Endocrinology 142:4244–4250.
Dakin, C. L., C. J. Small, R. L. Batterham, N. M. Neary, M. A. Cohen, M. Patterson, et al. 2004. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145:2687–2695.
De Angelis, K., R. B. Wichi, W. R. A. Jesus, E. D. Moreira, A. Mukharji, K. Miyasaka, V. Bucinskaite, et al. 2001. Cholecystokinin-8 receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8:359–371.
Foley, C. M., R. M. McAllister, and E. M. Hasser. 2001. Exercise training changes autonomic cardiovascular balance in mice. J. Appl. Physiol. 96:2174–2178.
DeWitt, C. R., and J. C. Waksman. 2004. Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. Toxicol. Rev. 23:223–238.
Druce, M. R., and M. Ghatei. 2006. Oxyntomodulin. Curr. Opin. Endocrinol. Diabetes 13:49–55.
Druce, M. R., C. J. Small, and S. R. Bloom. 2004. Minireview: gut peptides regulating satiety. Endocrinology 145:2660–2665.
Drucker, D. J. 2007. The role of gut hormones in glucose homeostasis. J. Clin. Invest. 117:24–32.
Dunphy, J. L., R. G. Taylor, and P. J. Fuller. 1998. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol. 141:179–186.
Foley, C. M., R. M. McAllister, and E. M. Hasser. 2001. Thyroid status influences baroreflex function and autonomic contributions to arterial pressure and heart rate. Am. J. Physiol. Heart Circ. Physiol. 280:H2061–H2068.
Gelling, R. W., X. Q. Du, D. S. Dichmann, J. Romer, H. Huang, L. Cui, et al. 2003. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. PNAS 100:1438–1443.
Gluck, E. F., N. Stephens, and S. J. Swapp. 2006. Peripheral ghrelin deepens torpor bouts in mice through the arcuate nucleus neuropeptide Y signaling pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 291:R1303–R1309.
Habegger, K. M., K. M. Heppner, N. Geary, T. J. Bartness, R. Dimarchi, and M. H. Tschop. 2010. The metabolic actions of glucagon revisited. Nat. Rev. Endocrinol. 6:689–697.
Hansen, L. H., N. Abrahamsen, and E. Nishimura. 1995. Glucagon receptor mRNA distribution in rat tissues. Peptides 16:1163–1166.
Heppner, K. M., K. M. Habegger, J. Day, P. T. Pfluger, D. Perez-Tilve, B. Ward, et al. 2010. Glucagon regulation of energy metabolism. Physiol. Behav. 100:545–548.
Jones, B. J., T. Tan, and S. R. Bloom. 2012. Minireview: glucagon in stress and energy homeostasis. Endocrinology 153:1049–1054.
Karra, E., and R. L. Batterham. 2010. The role of gut hormones in the regulation of body weight and energy homeostasis. Mol. Cell. Endocrinol. 316:120–128.
Kerns, W. 2007. Management of beta-adrenergic blocker and calcium channel antagonist toxicity. Emerg. Med. Clin. North Am. 25:309–331.
Kurosawa, M., S. Iijima, A. Funakoshi, T. Kawanami, K. Miyasaka, V. Bucinskaite, et al. 2001. Cholecystokinin-8 (CCK-8) has no effect on heart rate in rats lacking CCK-A receptors. Peptides 22:1279–1284.
Longuet, C., E. M. Sinclair, A. Maida, L. L. Baggio, M. Maziarz, M. J. Charron, et al. 2008. The glucagon receptor is required for the adaptive metabolic response to fasting. Cell Metab. 8:359–371.
Macneil, D. J., J. L. Occi, P. J. Hey, C. D. Strader, and M. P. Graziano. 1994. Cloning and expression of a human glucagon receptor. Biochem. Biophys. Res. Commun. 198:328–334.
Maida, A., J. A. Lovshin, L. L. Baggio, and D. J. Drucker. 2008. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 149:5670–5678.
Mayo, K. E., L. J. Miller, D. Bataille, S. Dalle, B. Goke, B. Thorens, et al. 2003. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol. Rev. 55:167–194.
Murphy, K. G., and S. R. Bloom. 2006. Gut hormones and the regulation of energy homeostasis. Nature 444:854–859.
Newton, C. R. H., J. H. Delgado, and H. F. Gomez. 2002. Calcium and beta receptor antagonist overdose: a review and update of pharmacological principles and management. Semin. Respir. Crit. Care Med. 23:19–25.
Palatini, P., E. Casiglia, P. Pauletto, J. Staessen, N. Kaciroti, and S. Julious. 1997. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 30:1267–1273.
Parker, J. C., K. M. Andrews, M. R. Allen, J. L. Stock, and J. D. McNeish. 2002. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290:839–843.
Parkinsson, J. R. C., W. S. Dhillo, C. J. Small, O. B. Chaudhri, G. A. Bewick, I. Pritchard, et al. 2008. PYY3-36 injection in
mice produces an acute anorexigenic effect followed by a delayed orexigenic effect not observed with other anorexigenic gut hormones. Am. J. Physiol. Endocrinol. Metab. 294:E698–E708.
Pocai, A. 2012. Unraveling oxyntomodulin, GLP1’s enigmatic brother. J. Endocrinol. 215:335–346.
Shepard, G. 2006. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers. Am. J. Health Syst. Pharm. 63:1828–1835.
Sorensen, H., M. S. Winzell, C. L. Brand, K. Fosgerau, R. W. Gelling, E. Nishimura, et al. 2006. Glucagon receptor knockout mice display increased insulin sensitivity and impaired β-cell function. Diabetes 55:3463–3469.
Sowden, G. L., D. J. Drucker, D. Weinshenker, and S. J. Swoap. 2007. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor. Am. J. Physiol. Regul. Integr. Comp. Physiol. 292:R962–R970.
Steiner, C., A. L. Wit, and A. N. Damato. 1969. Effects of glucagon on atrioventricular conduction and ventricular automaticity in dogs. Circ. Res. 24:167–177.
Stuesse, S. L., M. N. Levy, and H. Zieske. 1982. Effects of glucagon on cardiac chronotropic response to vagal stimulation in the dog. Am. J. Physiol. Heart Circ. Physiol. 242:H7–H12.
Swoap, S. J., C. Li, J. Wess, A. D. Parsons, T. D. Williams, and J. M. Overton. 2008. Vagal tone dominates autonomic control of mouse heart rate at thermoneutrality. Am. J. Physiol. Heart Circ. Physiol. 294:H1581–H1588.
Taboulet, P., A. Cariou, A. Berdeaux, and C. Bismuth. 1993. Pathophysiology and management of self-poisoning with beta-blockers. J. Toxicol. Clin. Toxicol. 31:531–551.
Takayama, K., K.-I. Yuhki, K. Ono, T. Fujino, A. Hara, T. Yamada, et al. 2005. Thromboxane A2 and prostaglandin F2[alpha] mediate inflammatory tachycardia. Nat. Med. 11:562–566.
Vuguin, P. M., and M. J. Charron. 2011. Novel insight into glucagon receptor action: lessons from knockout and transgenic mouse models. Diabetes Obes. Metab. 13:144–150.
Vuguin, P. M., M. H. Kedees, L. Cui, Y. Guz, R. W. Gelling, M. Nejathaim, et al. 2006. Ablation of the glucagon receptor gene increases fetal lethality and produces alterations in islet development and maturation. Endocrinology 147:3995–4006.
Watson, W. A., T. L. Litovitz, G. C. Rodgers, W. Klein-Schwartz, N. Reid, J. Youniss, et al. 2005. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 23:589–666.
Williams, T. D., J. B. Chambers, R. P. Henderson, M. E. Rashotte, and J. M. Overton. 2002. Cardiovascular responses to caloric restriction and thermoneutrality in C57BL/6J mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282:R1459–R1467.
Wynne, K., A. J. Park, C. J. Small, M. Patterson, S. M. Ellis, K. G. Murphy, et al. 2005. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54:2390–2395.
Wynne, K., A. J. Park, C. J. Small, K. Meeran, M. A. Ghati, G. S. Frost, et al. 2006. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int. J. Obes. 30:1729–1736.